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https://doi.org/10.1016/j.stemcr.2019.07.009SUMMARYIn vertebrates, GATA2 is a master regulator of hematopoiesis and is expressed throughout embryo development and in adult life.
Although the essential role of GATA2 in mouse hematopoiesis is well established, its involvement during early human hematopoietic
development is not clear. By combining time-controlled overexpression of GATA2 with genetic knockout experiments, we found that
GATA2, at the mesoderm specification stage, promotes the generation of hemogenic endothelial progenitors and their further differen-
tiation to hematopoietic progenitor cells, and negatively regulates cardiac differentiation. Surprisingly, genome-wide transcriptional and
chromatin immunoprecipitation analysis showed thatGATA2 bound to regulatory regions, and repressed the expression of cardiac devel-
opment-related genes. Moreover, genes important for hematopoietic differentiation were upregulated by GATA2 in a mostly indirect
manner. Collectively, our data reveal a hitherto unrecognized role of GATA2 as a repressor of cardiac fates, and highlight the importance
of coordinating the specification and repression of alternative cell fates.INTRODUCTION
During embryonic development, hematopoietic stem cells
(HSCs) emerge from hemogenic endothelium in the
ventral wall of the aorta-gonad-mesonephros (AGM) re-
gion (Dzierzak and Speck, 2008; Ivanovs et al., 2011,
2014), and their specification is tightly orchestrated by
temporal changes in the expression of master regulators
during endothelial-to-hematopoietic transition (EHT).
While animal models have been crucial in identifying
several master regulators, such as GATA2, RUNX1, and
TAL1 (Robert-Moreno et al., 2005; Wilson et al., 2010a,
2010b), how these factors drive human HSC emergence
during EHT remains poorly understood.
GATA2 belongs to an evolutionarily conserved family of
zinc finger transcription factors comprising six members:
GATA1 to GATA6 (Merika and Orkin, 1993; Molkentin,
2000). GATA2, together with GATA1 and GATA3, are cate-Stem Cell Repor
This is an open access artigorized as ‘‘hematopoietic’’ GATA factors and regulate the
development of diverse hematopoietic lineages (Bresnick
et al., 2012; Johnson et al., 2012; Katsumura et al., 2017;
Orkin, 1992). The importance of GATA2 in HSC specifica-
tionwas first highlighted by gene targeting studies, because
ablation of Gata2 is embryonic lethal at embryonic day (E)
10.5 due to the collapse of primitive and definitive hemato-
poiesis (Gao et al., 2013; Ling et al., 2004; Tsai and Orkin,
1997). Notably, analysis of chimeric embryos generated
with Gata2-null embryonic stem cells (ESCs) indicated
that these cells failed to contribute to any hematopoietic
lineage (Tsai et al., 1994). Likewise, mouse Gata2-null
endothelial cells failed to produce HSCs because of
impaired EHT (de Pater et al., 2013; Gao et al., 2013; John-
son et al., 2012; Lim et al., 2012). A primary role of GATA2
in promoting EHT has been recently demonstrated in hu-
mans (Gomes et al., 2018; Kang et al., 2018; Zhou et al.,
2019).ts j Vol. 13 j 515–529 j September 10, 2019 j ª 2019 The Author(s). 515
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In adult hematopoiesis, GATA2 is expressed at high levels
in HSCs, early hematopoietic progenitors, and in
erythroid/megakaryocyte lineages (Vicente et al., 2012).
Recent studies showed that GATA2 haploinsufficiency is
associated with some familial cases of myelodysplastic syn-
drome, bone marrow failure, immunodeficiency, and
MonoMAc syndrome (Dickinson et al., 2011; Hahn et al.,
2011; Wlodarski et al., 2016), further supporting its impor-
tant role in HSCs. Conversely, enforced expression of
GATA2 in cord blood-derivedHSCs confers increased quies-
cence, an important hallmark of HSCs (Tipping et al.,
2009).
We sought to explore the role of GATA2 during human
hematopoietic development by inducing GATA2 expres-
sion in differentiating human induced pluripotent stem
cells (hiPSCs) (Takahashi et al., 2007). We show that
GATA2 induction during mesoderm patterning robustly
promotes the generation of hemogenic endothelial pro-
genitors (HEPs), and their further differentiation into he-
matopoietic progenitor cells (HPCs). Global transcriptome
analysis and chromatin immunoprecipitation sequencing
(ChIP-seq) combined with DNA massive sequencing re-
vealed that GATA2 directly represses genes that promote
cardiac cell fate differentiation and activates master he-
matopoietic regulators via direct and indirect mechanisms.
Remarkably, GATA2 knockout impaired hematopoietic
development and enhanced cardiac potential of meso-
dermal progenitors.RESULTS
GATA2 Promotes Robust Hematopoietic
Differentiation
To analyze the impact of GATA2 in early human hemato-
poiesis, we first examined endogenous GATA2 expression
in hiPSCs induced to form embryoid bodies (EBs) in
serum-free medium with the successive addition of BMP4
(days 0–3), CHIR92001 (days 2–3), and hematopoietic cyto-
kines (days 3–15) (Figure 1A). This protocol promotes
mesoderm induction (days 2–3), specification of meso-
dermal cells to bipotential hemato-endothelial progenitors
(CD31+CD34+CD43-CD45; days 3–10) that can originate
both endothelial and hematopoietic cells and could be
considered equivalent to HEPs (Ayllon et al., 2015),
and further commitment of HEPs to definitive HPCs
(CD34+CD43+CD45+; days 10–15) (Giorgetti et al., 2017;
Sturgeon et al., 2014). GATA2 was initially expressed at
day 2 (Figure 1B), at the onset of mesoderm formation
marked by the expression of T and MIXL1 (Figure 1C). Its
expression then progressively increased along with the
emergence of HEPs and HPCs, in parallel with the master
hemogenic regulators RUNX1 and SCL (Figure 1B).516 Stem Cell Reports j Vol. 13 j 515–529 j September 10, 2019We next established transgenic hiPSCs in which the
expression of transgenic GATA2 could be temporally
controlled by doxycycline (Dox) administration (hereafter
termed iGATA2-hiPSCs) (Figure S1A). Robust transgenic
overexpression of GATA2 was confirmed in four clones
(CL6, CL9, CL201, CL204) derived from two independent
iGATA2-hiPSC lines by western blotting after 2 days of
Dox treatment (Figure S1B). qRT-PCR analysis and in vivo
functional assays showed that iGATA2-hiPSCs retained
the expression of pluripotency markers and also the capac-
ity to generate teratomas (Figure S1C).
Then, considering the expression of endogenousGATA2,
we induced GATA2 expression from day 2 to 7 in EBs
generated from iGATA2-hiPSCs (Figures 1A and S1D–
S1G). Flow cytometry analysis showed that enforced
expression of GATA2 significantly enhanced the produc-
tion of HEPs (2.5-fold increase of CD31+CD34+CD45
cells and 2-fold increase of CD34+CD43–CD45– cells) in
EBs at day 10 (Figures 1D and 1E), and promoted the gener-
ation of HPCs (5-fold increase of CD34+CD43+CD45+
cells) at day 15 (Figures 1D and 1E).
We used colony-forming unit (CFU) assays to confirm
that GATA2 overexpression promotes hematopoiesis from
iGATA2-hiPSCs. Dox treatment (days 2–7) significantly
increased the total number of hematopoietic CFCs in day
10 EBs (Figure 2A). Notably, CFU scoring revealed an
enhancement in all types of hematopoietic colonies (Fig-
ure 2A), suggesting that GATA2 expression promotes he-
matopoietic commitment by inducingmesodermal specifi-
cation to HEPs at very early stages.
To better understand the role of GATA2 in early hemato-
poiesis, we treated iGATA2-hiPSCs with Dox at distinct
stages of EB development (days 2–7, 7–15, and 10–15). In-
duction of GATA2 at days 2–7 had the greatest effect on
HEP and HPC generation (Figure 2B), while treatment at
days 7–15 had no significant effects on the HEP popula-
tion, and only a small effect was observed for early HPCs.
By contrast, GATA2 overexpression at days 10–15 led to a
significant decrease in HPC numbers (Figure 2B), consis-
tent with previous findings showing that high GATA2
expression in HSCs blocks normal hematopoiesis (Persons
et al., 1999; Tipping et al., 2009).
To address whether the higher hematopoietic output
could be a consequence of a higher HEP generation,
CD34+ cells were purified from day 10 EBs with or without
Dox treatment, and were cultured on OP9 stromal cells
(Choi et al., 2009; Ramos-Mejia et al., 2014) (Figure 2C, up-
per panel). After 4 days of coculture, both CD34+CD45+ and
total CD45+ cell subpopulations increased significantly in
the cocultures derived from Dox-treated cells (3- and
4-fold, respectively), whereas the number of HEPs decreased
slightly (Figure 2C, lower panel). To further characterize
the effect of GATA2 during mesoderm patterning, we
Figure 1. Early GATA2 Induction Enhances Hematopoietic Development from hiPSCs
(A) hiPSC hematopoietic differentiation based on EB generation.
(B) Time course of endogenous GATA2, SCL/TAL1, and RUNX1 expression during EB development, normalized to GAPDH.
(C) Time course of endogenous mesodermal marker expression (BRACHYURY and MIXL1) during EB development, normalized to GAPDH. In
(B) and (C), data represent the mean ± SD of three independent experiments.
(D) Representative flow cytometry analysis of HEPs (CD31+CD34+CD45– and CD34+CD43–CD45–) and HPCs (CD34+CD45+ and CD43+CD45+) in
EBs at days 10 and 15 in control and Dox-treated cells.
(E) Quantitative summary of HEP and HPC analysis at days 10 and 15 of EB differentiation in control and Dox-treated cells.
Data represent the mean ± SD of 10 independent experiments. *p < 0.05, ***p < 0.001.performed single-cell cloning assays of mesodermal cells
(KDR+CD34–CD31–) usingOP9 stromal cells and conditions
that support hemato-endothelial differentiation. Dox treat-ment slightly increased the hematopoietic/endothelial
ratio over control (no-Dox) (Figure S2A, upper table). We
repeated single-cell clonal analysis of CD31+CD34+CD43–Stem Cell Reports j Vol. 13 j 515–529 j September 10, 2019 517
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cells purified from day 7 EBs with or without Dox, finding
that Dox-treated cells showed an increased number of he-
matopoietic colonies but a smaller proportion of endothe-
lial growth (Figure S2A, lower table), overall increasing the
hematopoietic/endothelial ratio by >4-fold.
Because GATA2 has been associated with adult HSC sur-
vival (Tipping et al., 2009), we questioned whether the in-
crease in hematopoiesis was the consequence of GATA2-
mediated proliferation/survival of emerging HEPs and
HPCs. We analyzed apoptosis and cell-cycle distribution
after GATA2 induction in HEPs and HPCs at days 10 and
15 of EB development, respectively, finding that GATA2
induction did not affect survival or proliferation of differ-
entiating cells (Figures 2D, 2E, and S2B).
Overall, our data are consistent with recent reports (Kang
et al., 2018; Zhou et al., 2019) showing that, rather than in-
duction of HEP specification or the selective proliferation/
survival of HEPs/HPCs, GATA2 induces hematopoietic
development by promoting EHT.
GATA2 Activates the Hematopoietic Program and
Inhibits Cardiac Genes
To gainmechanistic insight into how GATA2 promotes he-
matopoietic development, we performed RNA sequencing
(RNA-seq) of fluorescence-activated cell sorting (FACS)-
sorted control or GATA2-overexpressing HEPs from day 2
to 7 of differentiation. We used the criteria of >1.5-fold
change and adjusted p value < 0.05 to identify differentially
expressed genes (DEGs) in the two treatment groups.
Among 1,127 genes significantly deregulated by
GATA2 induction, 700 were downregulated and 427
were upregulated (Table S2). Consistent with the in vitro
results, GATA2 activated a broad spectrum of genes
regulating HSC/HPC development (e.g., RUNX1, MYB,
STAT1, ITGA2B/CD41, SPN/CD43, SPI1/PU.1, ZBT3, and
ALDH1A1), as well as of genes of myeloid (CD33, CD53,
CD48, CSFR1, and MPO) and erythroid (NFE2, GATA1,
KLF1, HBZ, HBE1, HBA1, and HBG2) lineages (Figure S3A).
Proinflammatory cytokines have been proposed as positive
regulators of definitive hematopoiesis in the mouse AGMFigure 2. GATA2 Induction Promotes Hemogenic Endothelium Tra
(A) CFU potential of day 10 EB progenitors in control and Dox-treated c
and scored for the following morphological subsets: burst-forming
ulocyte, erythroid, macrophage, megakaryocyte (GEMM); CFU-granu
mean ± SD of the total number of colonies per 50,000 cells seeded o
(B) Quantitative summary of HEP and HPC analysis at days 10 and 15
represent the mean ± SD of 6 independent experiments.
(C) Schematic of sorted HEP cell differentiation using OP9 coculture
differentiate into CD34+/CD45+ and CD45+ hematopoietic cells (lower p
(D) Representative dot plots and bar graphs show cell-cycle analysis
Dox. Data represent the mean ± SD of 3 independent experiments.
(E) Apoptosis analysis in HEPs and HPCs in control and Dox-treated c
Data represent the mean ± SD of 3 independent experiments. *p < 0.region and its zebrafish equivalent (Espin-Palazon et al.,
2014; He et al., 2015; Sawamiphak et al., 2014). In accord
with this, gene ontology (GO) and gene set enrichment
analysis showed that GATA2-overexpressing HEPs were
highly enriched for genes associated with immune
response (IRF7, IFI27, IFIT1, TMEM173, IFI6, IFITM1,
TRIM6, TRIM14, and TRIM25) (Figure S3A). Surprisingly,
several highly significant GO categories of downregulated
genes were related to heart development and cardiogenesis
(Figure S3B), including transcription factors such as TBX3,
MYOCD, PTX2, NR2F2, and FOXC2, and structural genes
including TNNC1, RYR3, SPNS2, DVL3, SMO, NEBL,
HEG1, and CCM2L (Figure S3B).
Furthermore, expression of genes related to angiogenesis
and endothelial cell differentiation (JAG-1, KDR, SOX17,
PCDH12, TEK, ESM1, and SCUBE1) were also found to be
downregulated (Figure S3B). These data strongly suggest
that GATA2 has a dual activity during mesodermal
patterning.
GATA2 Directly Binds Cardiac Genes
To determine the direct effects of GATA2 on gene transcrip-
tion, we performed ChIP-seq analysis for GATA2 occu-
pancy on FACS-sorted GFP+ cells at day 7 of EB develop-
ment, coinciding with the maximum expression of the
GATA2 transgene (Figure S1E). We identified 2,097
GATA2 binding-associated genes (Figures 3A, S3C, and
S3D). GATA2 was found to be enriched around the tran-
scriptional start site of many genes harboring a GATA2
binding motif (Figures 3B–3D and S3E), indicating that
GATA2 does not occupy unscheduled genomic binding
sites in iGATA2-hiPSCs. Integrated analysis with RNA-seq
data indicated that only 8% of upregulated genes were
decorated with GATA2 (35 genes in total), whereas up to
20% of downregulated genes were occupied by GATA2
(143) (Figure 3E). Probabilistic analysis indicated that
GATA2 occupancy on repressed genes was significantly
higher than would be expected by random chance
(p < 1016), suggesting a predominant function of GATA2
repressing gene transcription during mesodermal lineagensition
ells. Colonies were counted from each group after 2 weeks of culture
unit-erythroid (E); CFU-granulocyte, macrophage (GM); CFU-gran-
locyte (CFU-G); and CFU-macrophage (CFU-M). Data represent the
f 6 independent experiments.
of EB differentiation following stepwise treatment with Dox. Data
(upper panel). GATA2-induced HEPs showed a higher capacity to
anel). Data represent the mean ± SD of 3 independent experiments.
using EdU and DAPI staining on HEPs and HPCs treated or not with
ells.
05, **p < 0.01, ***p < 0.001.
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differentiation (Figure 3E). Among the upregulated GATA2
target genes, we identified determinants for hematopoietic
development such as RUNX1 andNFE2 (Figures 3F and 3G).
Of note, several of the downregulated GATA2 target genes
were associated with heart development, such as TBX3
and PITX2 (Figures 3F and 3G), confirming the RNA-seq
data.
The specific binding of GATA2 to proximal gene regions
of cardiac regulators strongly suggests that GATA2 directly
controls the repression of genes involved in cardiac
development. To test this, we used a luciferase reporter
assay in COS7 cells for three cardiac genes (TBX3, PITX2,
and ISL-1), according to the ChIP-seq data. Luciferase
activity driven by the 30 UTR of the TBX3 promoter,
the 1,960/+369 region of the ISL-1 promoter, and
the 4,350/3,192 region of the PITX2 promoter, was
significantly reduced by GATA2 coexpression (Figure 3H).
Thus, in addition to validating GATA2 as a pro-hematopoi-
etic fate regulator, these data point to an additional and un-
described role for GATA2 in repressing cardiac regulation.
Single-Cell RNA-Seq of Mesodermal and Hemato-
Endothelial Progenitors
To better characterize the effect of GATA2 overexpression
on mesodermal diversification, we performed single-cell
RNA-seq (scRNA-seq) on FACS-purified mesodermal
(KDR+CD34–CD31–; EBs d5) and hemato-endothelial pro-
genitor (KDR+CD34+CD43–; EBs d7) cells with or without
Dox (Figure S4A). EB-derived cells fromday 2were profiled
as the starting population.
In unsupervised clustering based on the Seurat method
(Butler et al., 2018), we identified five transcriptionallyFigure 3. Identification of GATA2 Target Genes during Mesoderm
(A) Venn diagram indicating the overlap between the number of genes
in EBs (plus Dox).
(B) MEME-ChIP motif analysis on the sequence of the GATA2 peaks i
GATA2 motifs at the center of the ChIP-seq peaks, as the top-ranked
(C) Genomic distribution of ChIP-seq peaks of GATA2 compared with th
the distribution of GATA2 peaks corrected by the genome-wide distrib
chart indicates that GATA2 preferentially occupies TSS neighborhood
is the region within 2.5 and 0.5 kbp upstream of the TSS. The PROXIM
CoDing Sequence. INTRONS are intronic regions. INTERGENIC is the re
(D) Meta-gene plot showing the GATA2 ChIP-seq profile occupancy in i
TSS until +5 kb of transcription end site (TES).
(E) Histogram of the proportion of GATA2 target genes deregulated af
discovery rate < 0.05) during EB development (p value was calculate
(F) Functional analysis on the mammalian phenotype enrichment on
(G) UCSC genome browser screenshots of several developmental hema
(H) Relative luciferase activity of COS7 cells transfected with reporter
30 UTR genes and pWPI-GATA2 plasmid. Relative luciferase activity is s
with mock vector.
A representative result of three independent experiments performed in
using Student’s t test; *p < 0.05, **p < 0.01.distinct cell clusters (Figure 4A). The t-distributed stochas-
tic neighbor embedding (t-SNE) projection visualized that
day 2 EB-derived cells formed one expression signature
cluster, whereas mesodermal (day 5) and hemato-endothe-
lial (day 7) cells showed the presence of two subpopula-
tions in each cluster (Figure 4B). We assigned biological
identities to each cluster based on the expression of key
marker genes (adjusted p value < 0.05) (Table S3). Cluster
1 (EBs day 2) showedhigh expression of pluripotency genes
(NANOG,OCT4/POU5f1, ZFP42/REX1,DPPA4, and SALL2),
indicating maintenance of undifferentiated pluripotent
cells. Cluster 2 (mesodermal S1) showed a multi-lineage
mesodermal identity (BMP4, MSX2, PDGFRA, LGR5,
CDX2, FRZB, HOXA1, BMP5, FTH1, WNT5A, WNT5B,
HAND1, TNNT1, and TBX3). Cluster 3 (mesodermal S2)
lacked expression of mesodermal markers, but co-ex-
pressed ETV2, its target SCL/TAL1, and EGFL7, which are
responsible for restricting mesoderm specification to endo-
thelium fate (Wareing et al., 2012), and genes suggestive of
a mesenchymal phenotype (COL1A1, COL6A3, COL3A1,
COL6A2, ACTA2, and LUM). Cluster 4 (hemato-endothelial
S1) and cluster 5 (hemato-endothelial S2) shared the
expression of several key hemato-endothelial markers
(CDH5, PECAM1, ICAM2, CD40, ESAM, FLI1, ERG, ETS1,
and HHEX); however, hemato-endothelial S2 cells showed
a more restrictive endothelial identity (expressing selec-
tively NOTCH4, SOX7, NRP2, TEK, and NOS3). Also, we
noted that hemato-endothelial S1 was enriched for genes
that regulate cell cycle (AURKB, TOP2A, CDK1, MKI67,
BRCA2, CASC5, and CDCA5).
Next, we retrospectively colored each cluster on the basis
of Dox andno-Dox conditions (Figure 4C). For each cluster,Specification
found targeted by GATA2 in each replicate of the ChIP-seq of GATA2
n two independent ChIP-seq replicates showing an enrichment of
motif.
e whole genome in two independent clones. The pie chart represents
ution of each gene feature (background circle distribution). The pie
regions, including 50 UTR and PROXIMAL regions. The DISTAL region
AL region is the region within 0.5 kbp of the TSS. CDS is the protein
mainder of the genome. TSS is the transcription start site.
PSCs (CL6 no-Dox) and EBs (CL6 plus Dox) and IgG from5 kb of the
ter induction of GATA (iGATA2) (up or down, 1.5-fold change, false
d using chi-square test).
tology for the deregulated GATA2 target genes (MGI database).
topoietic and cardiac genes targeted by GATA2.
plasmids for ISL1 (1,960/+369), PITX2 (4,350/3,192), or TBX3
hown as the ratio of luciferase activity to that in cells cotransfected
triplicate is shown as the mean ± SD. Differences were determined
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the number of cells per condition was calculated and
each Dox condition was compared with that of the corre-
sponding no-Dox condition (Table S3). A chi-square test
showed that treatment and cluster populations were not
independent (p = 0.0002687). Considering an adjusted
p value < 0.05, the post hoc comparisons showed that, at
day 5 of EB development, the proportion of mesodermal
S1 cells increased significantly in Dox conditions
(chi-square = 6.816191, adjusted p value = 0.018067005)
(Figure 4D). At day 7, GATA2 overexpression induced
an enrichment of the hemato-endothelial S1 cluster
(chi-square = 3.082502, adjusted p value = 0.079138704)
(Figure 4D).
Based on these data, we speculate that GATA2 enhances
the proportion of cells with a multi-lineage mesodermal
signature and further increases the probability, at the sin-
gle-cell level, that a mesodermal progenitor acquired a
hemato-endothelial transcriptional profile. These data are
consistent with our FACS analysis (Figure S4A) and are in
line with recent findings showing that GATA2 overexpres-
sion enhances the generation of mesodermal cells and
further promotes EHT (Zhou et al., 2019).
Finally, we performed a new clustering analysis of meso-
dermal (day 5) and hemato-endothelial single cells (day 7)
based on DEGs (1,127 genes) identified in our bulk RNA-
seq analysis (HEPs day 10) (Table S4). Using t-SNE and hier-
archical clustering to visualize the data, five main clusters
were found (Figures S4B and S4C). GO enrichment analysis
and over-representation analysis (Boyle et al., 2004) re-
vealed that cluster 0 and cluster 4 were associated with
hemato-endothelial progenitors (ESCR, CDH5, ERG,
SOX17, and HOXA9), cluster 3 mesoderm (TBX3 and
MSX1), cluster 1 mesenchymal (FN1, LAMA1, and
COL5A1), and cluster 2 epiblast (EPCAM and CDH1) (Fig-
ure S4D). These data are in line with the scRNA-seq analysis
and suggest that most of the DEGs (1,056 genes) of day 10
were already differentially expressed in our single cells at
d5 and d7.
GATA2 Knockout Inhibits Hematopoietic
Development and Favors Cardiomyogenesis
Our results so far strongly suggest that transient GATA2
expression promotes hematopoietic differentiation and
represses alternative mesodermal fates during HEP specifi-
cation. To address whether GATA2 is necessary for specifi-
cation of HEPs, we used CRISPR/Cas9 gene editing toFigure 4. Single-Cell RNA-Seq Analysis Reveals GATA2 as a Driver
(A) Heatmap showing the expression pattern of top 10 gene markers
indicates assigned cluster. Red indicates the highest scaled expressio
(B) t-SNE visualization plot of day 2 (d2) EBs, mesodermal d5 and he
(C) t-SNE visualization plot of single cells of each cluster retrospecti
(D) Stacked bar diagram showing the percentage of cells in each clustarget exon 2 of GATA2 and generate knockout hiPSC-
GATA2 clones (hiPSC-GATA2KO). After expanding individ-
ual clones, we selected two targeted clones with biallelic
mutations (CL14 and CL19; Figure 5A). Immunocyto-
chemistry and qRT-PCR analysis confirmed the absence
of GATA2 expression during hiPSC-GATA2KO differentia-
tion (Figures S5A and S5B). No predicted CRISPR off-targets
were detected by genomic sequencing of hiPSC-GATA2KO
clones (Figure S5C). The hiPSC-GATA2KO clones retained
a normal karyotype and maintained the expression of plu-
ripotency markers (Figures S5D and S5E), confirming that
the GATA2 knockout is compatible with human stem cell
pluripotency.
We differentiated wild-type and hiPSC-GATA2KO clones
into hematopoietic cells as described earlier (see Figure 1A).
As expected, GATA2 knockout significantly affected
HEP generation (CD31+CD34+CD45–) in day 10 EBs (Fig-
ure 5B) and markedly decreased the number of HPCs
(CD34+CD43+CD45+) in day 15 EBs (Figure 5B). Moreover,
we consistently failed to detect hematopoietic CFCs at day
10 of EB development (data not shown).
In line with the transcription and ChIP-seq data, qRT-
PCR analysis revealed that the cardiac regulators TBX3,
NKX2.5, and MYOCD were progressively upregulated dur-
ing hiPSC-GATA2KO EB development, whereas the hemato-
poietic transcription factors SCL, GATA1, and PU.1 were
markedly suppressed (Figure 5C).
As these observations strongly suggest that interfering
with GATA2 expression might be an effective strategy to
generate cardiomyocytes ex vivo, we differentiated hiPSC-
GATA2KO and iGATA2-hiPSC lines (with or without Dox
administration, days 2–7) to cardiomyocytes using a
well-characterized protocol (Lian et al., 2013) (Figure 6A),
and measured the expression of the cardiac structural
proteins troponin I (cTnI) and myosin heavy chain
(MHC) after 20 days. Remarkably, we found a 3-fold in-
crease in the number of cTnI+ MHC+ cells in differentiated
hiPSC-GATA2KO cells compared with iGATA2-iPSC cells in
the absence of Dox (Figures 6B and 6C). Conversely, Dox
administration led to a significant decrease in the number
of cTnI+ MHC+ cells in the iGATA2-iPSC line (Figures 6B
and 6C). As a functional readout of cardiomyocyte genera-
tion, we monitored for the appearance of beating cells.
Whereas the majority of hiPSC-GATA2KO cells started
beating at days 8–10 of differentiation and persisted
throughout the 20-day experiment (Videos S1 and S2),of Hemato-Endothelial Specification
distinguishing 5 clusters from scRNA-seq analysis. Colored top bar
n and blue the lowest.
mato-endothelial d7 cells according to clusters in (A).
vely colored by Dox (red) and no-Dox treatment (gray).
ter with respect to treatment conditions.
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Figure 5. GATA2 Is Essential for HPC Development
(A) Representative sequencing of targeted homozygous hiPSC clones at the GATA2 locus using sgRNA1 and sgRNA2; PAM sequences are
labeled in yellow.
(B) Quantitative summary of HEP and HPC FACS analysis at d10 and d15 of EB development in wild-type (WT) and hiPSC-GATA2KO clones.
Data represent the mean ± SD fold change relative to WT iPSC lines.
(C) qRT-PCR analysis of hematopoietic and cardiac regulators in WT and hiPSC-GATAKO clones during EB development.
Data represent the mean ± SD of 3 independent experiments. **p < 0.01, ***p < 0.001.
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Figure 6. GATA2 Knockout Promotes Car-
diomyocyte Differentiation
(A) Schematic of the cardiomyocyte differ-
entiation protocol.
(B) Representative FACS analysis of the
percentage of cTnI+ MHC+ cells in hiPSC-
GATA2KO and iGATA2-iPSC lines (with and
without Dox treatment) at day 20 of
differentiation.
(C) Bar graph showing the mean percentage
of cTnI+ MHC+ cells in (B). Data represent
the mean ± SD of 3 independent experi-
ments. *p < 0.05, ***p < 0.001.very few iGATA2-iPSC cells treated with Dox were beating
(Video S3). Taken together, these results suggest that
GATA2 is both an activator of hematopoiesis and a
repressor of cardiac cell fate.DISCUSSION
GATA2 has long been implicated as a master regulator of
murine hematopoiesis (Tsai et al., 1994; Tsai and Orkin,
1997), and its dysregulation is associated with human
immunodeficiency syndromes (Spinner et al., 2014). How-
ever, its role in early human hematopoiesis is less clear. Hu-
man iPSCs are a useful model to interrogate the molecular
mechanisms driving early hematopoietic development.
To our knowledge, this is the first study showing a dual
activity of GATA2 in human early hematopoiesis. We
show that GATA2 drives mesoderm progenitors to differen-
tiate into blood cells and represses cardiac fates. Indeed, our
GATA2 knockout model confirmed that loss of GATA2 ac-
tivity impairs hematopoietic development and enhances
cardiomyocyte differentiation.
Earlier studies both in vivo and in stem cell models sug-
gested that hematopoietic and cardiac lineages develop in
close proximity and are mutually antagonistic (Bussmann
et al., 2007; Chagraoui et al., 2018; Chan et al., 2013; Freireet al., 2017; Kouskoff et al., 2005; Liu et al., 2013; Schoene-
beck et al., 2007; Van Handel et al., 2012). For example,
overexpression of Scl in mesodermal cells promotes he-
matopoietic development at the expense of cardiomyogen-
esis in differentiated mouse ESCs (Ismailoglu et al., 2008),
whereas Scl-deficient mice show ectopic cardiomyocytes
in yolk salc endothelium and die at E9.5 due to the com-
plete absence of hematopoiesis (Shivdasani et al., 1995;
Van Handel et al., 2012). Similarly, Etv2/Er71 deficiency
leads to a complete block of hemato-endothelial develop-
ment and a concomitant expansion of the cardiac lineage
in mutant embryos (Koyano-Nakagawa and Garry, 2017;
Lee et al., 2008; Liu et al., 2012; Rasmussen et al., 2011),
whereas Etv2 overexpression in differentiating mouse
ESCs shows the opposite phenotype (Liu et al., 2012).
To date, a direct role for GATA2 in cardiac development
has not been demonstrated. Gata2-null mice have no
apparent cardiovascular phenotype, but to our knowledge
studies specifically addressing heart malformation in
Gata2 mutants have not been performed. Whether
GATA2 overexpression in vivo enhances hematopoietic
cell specification while concurrently retarding cardiac
development should be addressed in the future.
GATA2 is known to cooperate with ER71/ETV2 and
SCL/TAL1 to regulate endothelial and hematopoietic pro-
grams in stem cells (Elcheva et al., 2014; Shi et al., 2014).Stem Cell Reports j Vol. 13 j 515–529 j September 10, 2019 525
The recent observation that coexpression of ER71/ETV2,
SCL/TAL1, and GATA2 during mouse ESC differentiation
enhances FLK-1+ hemangioblast production while block-
ing cardiac output (Liu et al., 2013) suggests a critical regu-
latory relationship between these factors duringmesoderm
diversification. Nevertheless, the gene regulatory network
governing hematopoietic and cardiac development is
poorly understood. Our bulk RNA-seq data revealed that
GATA2 overexpression failed to upregulate ER71/ETV2
expression in our HEP model, which is consistent with
the finding that ER71 is expressed before GATA2 during
both early mouse and ESC development (Liu et al., 2013).
Based on recent studies (Chagraoui et al., 2018; Org et al.,
2015), it is reasonable to presume that GATA2 and SCL
collaborate to promote blood specification at the expense
of cardiac fates. Yet, our deep DNA motif enrichment anal-
ysis of GATA2 targets demonstrate the absence of SCL bind-
ing sites (CANNTG) in both GATA2-bound activated and
repressed genes, which suggests that these two factors—at
least in our experimental model—act independently. Of
note, recent analysis at the single-cell level revealed that
only a subset of mouse E8.5 Scl/ endothelial cells upregu-
lated expression of a few cardiac-related genes. However,
those cells did not display a full cardiomyocyte transcrip-
tional program and continued to express key endothelial
markers (Pijuan-Sala et al., 2019; Scialdone et al., 2016).
Therefore, the role of SCL in the specification of hemato-
poietic fate and as a cadiac repressor needs to be
determined.
ChIP-seq indicated that GATA2 acts more as a repressor
than an activator during mesodermal diversification. Spe-
cifically, GATA2 binds directly to cardiac regulator pro-
moters, leading to their downregulation. Although previ-
ous studies in HPCs and mature blood cells have shown
that endogenous GATA2 preferentially occupies sites
distant to promoters (Calero-Nieto et al., 2014; Fujiwara
et al., 2009; Huang et al., 2016; Wilson et al., 2015), our
analysis revealed GATA2 binding promoter regions.
Whether this apparent discrepancy is a consequence of
cell-type-specific differences in GATA2 occupancy, the
fact that GATA2 is overexpressed in our studies, or both,
is unclear.
Enforced expression of instructive factors is an accepted
strategy to guide lineage fate commitment (Doulatov
et al., 2013; Elcheva et al., 2014; Nakajima-Takagi et al.,
2013; Navarro-Montero et al., 2017; Ramos-Mejia et al.,
2014; Sugimura et al., 2017), and offers the possibility to
generate any differentiated cell type fromhPSCs. Our study
provides cellular and molecular evidence that GATA2
induction promotes an enhancement of mesodermal cells
with hemato-endothelial potential, and decreases the
probability that alternative mesodermal fates occur.
Accordingly, GATA2 could be a target for manipulation to526 Stem Cell Reports j Vol. 13 j 515–529 j September 10, 2019improve the yield of target cells (blood or cardiomyocytes)
from hPSCs for drug screening and disease modeling.
In summary, we establish a novel role for GATA2 during
mesodermal lineage specification and provide new insights
into the complex regulatory network that controls human
early hematopoietic development.EXPERIMENTAL PROCEDURES
Human iPSC Culture
Human GATA2-hiPSC and iPSC-GATA2KO lines were maintained
on Matrigel-coated 60-mm plates in mTESR1 medium (Giorgetti
et al., 2017). Culture medium was changed daily and cells were
passaged weekly by EDTA dissociation.EB-Based Hematopoietic Differentiation
Human iPSCs were differentiated as described (Giorgetti et al.,
2017). In brief, EBs were treated with the GSK3 inhibitor
CHIR99021 (3 mM) from day 2 to 3 of culture (Sturgeon et al.,
2014). From day 3, EBs were cultured in differentiation medium
until day 15. To induce transgene GATA2 expression Dox
(1 mg/mL) was added from day 2 to 7 of differentiation.Cardiac Differentiation
Human iPSCs were differentiated inmonolayer cultures withmod-
ulators of canonical Wnt signaling (Lian et al., 2013). Contracting
cardiomyocytes could be observed between day 8 and 10 of differ-
entiation. Differentiated cells were disaggregated at day 20 with
0.25% trypsin-EDTA for 5–8 min at 37C for FACS analysis.ChIP-Seq Combined with DNA Massive Sequencing
GATA2-iPSCs (CL6 and CL9) were differentiated in the presence of
Dox (from day 2 to 7). ChIP experiments were performed with
1.53 106 cells using the ChIP-IT High Sensitivity Kit from Active
Motif (no. 53040), and specific antibodies for GATA2 (Santa Cruz;
sc-9008) or rabbit IgG as isotype control (Abcam; 172730),
Libraries were prepared according to Illumina instructions and
sequenced using the HiSeq 2000 platform (Illumina).Statistical Analysis
All data are expressed as mean ± SD. Statistical comparisons were
performed using Student’s t test (95% confidence interval). Statis-
tical significance was defined as p < 0.05.
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